Tratamiento del tabaquismo en fumadores con enfermedad pulmonar obstructiva crónica

Smoking is the most preventable and controllable health risk. Therefore, all health care professionals should give their utmost attention to and be more focused on the problem of smoking. Tobacco is a highly profitable product, because of its large-scale production and great number of consumers. Smoking control policies and treatment resources for smoking cessation have advanced in recent years, showing highly satisfactory results, particularly in Brazil. However, there is yet a long way to go before smoking can be considered a controlled disease from a public health standpoint. We can already perceive that the behavior of our society regarding smoking is changing, albeit slowly. Therefore, pulmonologists have a very promising area in which to work with their patients and the general population. We must act with greater impetus in support of health care policies and social living standards that directly contribute to improving health and quality of life. In this respect, pulmonologists can play a greater role as they get more involved in treating smokers, strengthening anti-smoking laws, and demanding health care policies related to lung diseases.

show abstract

“…Smoking cessation results in decreased dyspnea, slowing of COPD progression, and reduced frequency of exacerbations. 11 , 35 , 36 …”

Section: Smoking and Copdmentioning

confidence: 99%

Smoking control: challenges and achievements

Silva

Araújo

Queiroz³

et al. 2016

J. bras. pneumol.

View full text Add to dashboard Cite

show abstract

“…Smoking cessation is a medical objective in patients with an elevated risk of developing smoking-related health problems or who already have them, as is the case with COPD. 5 , 7 , 8 Moreover, smoking cessation in these patients has been shown to be associated with substantial savings for the Spanish National Health System (NHS), particularly in the health care-related component of costs, which are currently financed with public funds. 9 – 11 …”

Section: Introductionmentioning

confidence: 99%

Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain

Jiménez-Ruíz¹,

Solano-Reina²,

Signes-Costa³

et al. 2015

COPD

View full text Add to dashboard Cite

The aim of the study was to assess the budgetary impact of funding smoking-cessation drugs in COPD patients in Spain. A hybrid model (cohort and Markov) was developed for a 5-year time horizon. Only approved cessation drugs (varenicline, bupropion, and nicotine replacement therapy) were considered. Irrespective of the drug, the model allowed for an initial cessation attempt, and up to three additional attempts in case of failure or smoking relapse during a 5-year period. Drug effectiveness was based on controlled clinical trials. National Health System perspective was applied; therefore, only medical resources were included. The pharmaceutical costs for smoking-cessation drugs, extra medical follow-up as a consequence of public reimbursement, and annual savings for health costs avoided due to stopping smoking were considered. The model estimated that 17,756 COPD patients would stop smoking if public funding was available, compared with 1,303 without reimbursement. In the reimbursement scenario, the savings accounted for a total of €48.0 million, compensating for expenditures on drugs and medical visits (€40.4 million). Accumulated total additional savings in 5 years (€4.3 million) compared with the scenario without reimbursement was shown. Sensitivity analyses supported the results robustness. Funding smoking-cessation drugs in COPD patients seems to be an efficient option and a National Health System drug reimbursement scheme would represent a cost-saving policy in Spain.

show abstract

“…An increase in the mortality of smoking ILD patients has been reported, although the level of evidence was low. 8 Recently, more intensive smoking cessation therapy has been proposed for a subgroup of smokers, such as COPD patients, due to the higher levels of consumption and dependence observed in this population. 8 , 9 COPD treatment guidelines emphasize smoking cessation given that up to 40% of COPD patients continue to smoke.…”

mentioning

confidence: 99%

High Follow-up Rate in Smokers With Diffuse Interstitial Lung Diseases: A Magnificent Opportunity for Tobacco Cessation Treatment?

Frino-García,

Hernández-González,

Albacar

et al. 2024

Open Respiratory Archives

View full text Add to dashboard Cite

Tratamiento del tabaquismo en fumadores con enfermedad pulmonar obstructiva crónica

Cited by 20 publications

References 38 publications

Smoking control: challenges and achievements

Smoking control: challenges and achievements

Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain

High Follow-up Rate in Smokers With Diffuse Interstitial Lung Diseases: A Magnificent Opportunity for Tobacco Cessation Treatment?

Contact Info

Product

Resources

About